Nasopharyngeal cancer

In a randomised study of 38 patients with stage I-IV nasopharyngeal carcinoma following standard radiotherapy with or without chemotherapy, there was an improvement in the rate of metastasis in patients given PSK(14% ,3/21) compared with patients in the control group without PSK (35%, 6/17 )29 but the difference was not statistically significant (p =0.24).

The median survival (35 months versus 25 months, p<0.043) and 5-year survival rates(28% (6/23) versus 15% (2/17), p<0.043) were significantly better in the PSK treatment group (Fig. 7). It was concluded that PSK may be a useful immunotherapeutic agent in the management of nasopharyngeal cancer.

fig 7